AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38819500 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent blood in stool
Number of subjects: 1052
Study 38819500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard stools
Number of subjects: 1052
Study 38819614 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with VM and photophobia
Number of subjects: 366
Study 38819614 — intervention group
Group type: COMPARATOR
Intervention: Patients without photophobia
Number of subjects: 366
Study 38819614 — intervention group
Group type: COMPARATOR
Intervention: Control participants (healthy individuals)
Number of subjects: 366
Study 38819658 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg sebetralstat
Number of subjects: 136
Study 38819658 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg sebetralstat
Number of subjects: 136
Study 38819658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 38819882 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 943
Study 38819882 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 943
Study 38819917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (PediaFlù) plus standard of care (SoC)
Number of subjects: 120
Study 38819917 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 120
Study 38819923 — intervention group
Group type: COMPARATOR
Intervention: SBIRT-A-Standard
Number of subjects: 2300
Study 38819923 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT-A-Family
Number of subjects: 2300
Study 38819983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 210
Study 38819983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 210
Study 38819983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 38820078 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (80 mg once daily)
Number of subjects: 405
Study 38820078 — intervention group
Group type: COMPARATOR
Intervention: Investigator-selected TKIs
Number of subjects: 405
Study 38820078 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (in imatinib stratum)
Number of subjects: 405
Study 38820078 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 405
Study 38820078 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib (in second-generation TKI stratum)
Number of subjects: 405
Study 38820078 — intervention group
Group type: COMPARATOR
Intervention: Second-generation TKIs
Number of subjects: 405
Study 38820078 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib
Number of subjects: 405
Study 38820246 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide UTT and TB screening (Arm A)
Number of subjects: 38474
Study 38820246 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide UTT and TB screening (Arm A) among PLHIV
Number of subjects: 38474
Study 38820246 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (Arm C)
Number of subjects: 38474
Study 38820246 — intervention group
Group type: COMPARATOR
Intervention: Community-wide universal HIV testing with treatment following national guidelines and TB screening (Arm B)
Number of subjects: 38474
Study 38820294 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild CKD group
Number of subjects: 184
Study 38820342 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) based on non-HLA SNPs
Number of subjects: 784
Study 38820342 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs6749137
Number of subjects: 784
Study 38820342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis of PRS genes
Number of subjects: 784
Study 38820345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 382
Study 38820345 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diabetes management care)
Number of subjects: 382
Study 38820372 — intervention group
Group type: EXPERIMENTAL
Intervention: FUJIFILM SILVAMP TB LAM (FujiLAM)
Number of subjects: 1637
Study 38820379 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-assistive apps (SuperVision+, Seeing AI, or Aira) with one-on-one training
Number of subjects: 116
Study 38820379 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation option for training
Number of subjects: 116
Study 38820379 — intervention group
Group type: COMPARATOR
Intervention: Seeing AI app
Number of subjects: 116
Study 38820379 — intervention group
Group type: COMPARATOR
Intervention: Participants from New England
Number of subjects: 116
Study 38820379 — intervention group
Group type: COMPARATOR
Intervention: Participants with optical magnifier
Number of subjects: 116
Study 38820379 — intervention group
Group type: COMPARATOR
Intervention: Age and cognitive scores
Number of subjects: 116
Study 38820422 — intervention group
Group type: EXPERIMENTAL
Intervention: Luspatercept (1.0-1.75 mg/kg, 21-day cycles)
Number of subjects: 95
Study 38820520 — intervention group
Group type: EXPERIMENTAL
Intervention: Music only
Number of subjects: 30
Study 38820520 — intervention group
Group type: EXPERIMENTAL
Intervention: Music + tES
Number of subjects: 30
Study 38820520 — intervention group
Group type: COMPARATOR
Intervention: tES only (control condition)
Number of subjects: 30
Study 38820549 — intervention group
Group type: EXPERIMENTAL
Intervention: ivonescimab plus chemotherapy
Number of subjects: 322
Study 38820549 — intervention group
Group type: COMPARATOR
Intervention: placebo plus chemotherapy
Number of subjects: 322
Study 38820549 — intervention group
Group type: EXPERIMENTAL
Intervention: ivonescimab
Number of subjects: 322
Study 38820549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 322
Study 38820577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient sensor system-derived digital biomarkers (DomoHealth SA and Emfit QS device)
Number of subjects: 24
Study 38820577 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro b-type natriuretic peptide measurement
Number of subjects: 24
Study 38820586 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioral Therapy (ICBT) with text messaging adjunct
Number of subjects: 20
Study 38820586 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging in 3 categories: appreciating alliance, alliance building disclosures, agreement confirmation
Number of subjects: 20
Study 38820857 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP) administered before exercise
Number of subjects: 20
Study 38820857 — intervention group
Group type: EXPERIMENTAL
Intervention: No methylphenidate (MP) administered (without MP)
Number of subjects: 20
Study 38820857 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ADHD)
Number of subjects: 20
Study 38820888 — intervention group
Group type: EXPERIMENTAL
Intervention: IRX-2 plus durvalumab
Number of subjects: 16
Study 38820979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy
Number of subjects: 327
Study 38820979 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 327
Study 38821083 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax-obinutuzumab
Number of subjects: 926
Study 38821083 — intervention group
Group type: EXPERIMENTAL
Intervention: venetoclax-obinutuzumab-ibrutinib
Number of subjects: 926
Study 38821083 — intervention group
Group type: COMPARATOR
Intervention: chemoimmunotherapy
Number of subjects: 926
Study 38821083 — intervention group
Group type: COMPARATOR
Intervention: venetoclax-rituximab
Number of subjects: 926
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative incidence of major adverse cardiovascular events among survivors
Number of subjects: 9602
Study 38821086 — intervention group
Group type: COMPARATOR
Intervention: Cumulative incidence of major adverse cardiovascular events among community controls
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative burden of major adverse cardiovascular events in survivors
Number of subjects: 9602
Study 38821086 — intervention group
Group type: COMPARATOR
Intervention: Cumulative burden of major adverse cardiovascular events in community controls
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: One non-major adverse cardiovascular condition
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Two non-major adverse cardiovascular conditions
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Three non-major adverse cardiovascular conditions
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 arrhythmias
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 left ventricular systolic dysfunction
Number of subjects: 9602
Study 38821086 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 valvular disorders
Number of subjects: 9602
Study 38821260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet
Number of subjects: 100
Study 38821260 — intervention group
Group type: COMPARATOR
Intervention: Standard GL diet
Number of subjects: 100
Study 38821260 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 100
Study 38821260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load (GL) diet and calorie restriction (CR)
Number of subjects: 100
Study 38821261 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual multiteam systems (VMTS) for caregiver-implemented intervention
Number of subjects: 240
Study 38821261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-site data collection activities
Number of subjects: 240
Study 38821453 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aortic valve replacement (surgical or transcatheter)
Number of subjects: 2844
Study 38821453 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (control group)
Number of subjects: 2844
Study 38821545 — intervention group
Group type: EXPERIMENTAL
Intervention: 'My Bowels on Track' smartphone application with weekly/biweekly electronic patient-reported outcomes (PROs) and alerting system.
Number of subjects: 40
Study 38821545 — intervention group
Group type: EXPERIMENTAL
Intervention: 'My Bowels on Track' smartphone application with alerting system.
Number of subjects: 40
Study 38821574 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-guided approach
Number of subjects: 7584
Study 38821574 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 7584
Study 38821658 — intervention group
Group type: EXPERIMENTAL
Intervention: 660 nm diode laser
Number of subjects: 9
Study 38821658 — intervention group
Group type: EXPERIMENTAL
Intervention: 970 nm diode laser
Number of subjects: 9
Study 38821658 — intervention group
Group type: EXPERIMENTAL
Intervention: 445 nm diode laser
Number of subjects: 9
Study 38821658 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser treatment)
Number of subjects: 9
Study 38821718 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus relatlimab
Number of subjects: 50
Study 38821761 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary management of acute myocardial infarction
Number of subjects: 19000
Study 38821761 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period linked with the French national health database
Number of subjects: 19000
Study 38821761 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of medical care costs for index hospitalization and follow-up
Number of subjects: 19000
Study 38821761 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigating determinants of prognosis (including periodontal disease and sleep-disordered breathing)
Number of subjects: 19000
Study 38821945 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic distal gastrectomy (RDG)
Number of subjects: 300
Study 38821945 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic distal gastrectomy (LDG)
Number of subjects: 300
Study 38821996 — intervention group
Group type: EXPERIMENTAL
Intervention: Tattooed skin
Number of subjects: 16
Study 38821996 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent tattoos older than 1 year
Number of subjects: 16
Study 38822042 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired RAP variation (defined as end-expiratory RAP - end-inspiratory RAP ≤ 2 mm Hg)
Number of subjects: 75
Study 38822042 — intervention group
Group type: COMPARATOR
Intervention: Preserved RAP variation
Number of subjects: 75
Study 38822190 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of patent foramen ovale (PFO)
Number of subjects: 450
Study 38822245 — intervention group
Group type: EXPERIMENTAL
Intervention: Juggling three times a week during four weeks
Number of subjects: 26
Study 38822245 — intervention group
Group type: COMPARATOR
Intervention: No juggling (control phase) for four weeks
Number of subjects: 26
Study 38822300 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for 48 weeks
Number of subjects: 130
Study 38822324 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive stimulation using HappyNeuron PRESCO software App on tablets, with three 20-minute sessions (first supervised by a neuropsychologist).
Number of subjects: 55
Study 38822324 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive stimulation sessions.
Number of subjects: 55
Study 38822342 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 0
Study 38822391 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (sympatholytic), 6 weeks treatment
Number of subjects: 41
Study 38822391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (diuretic), 6 weeks treatment
Number of subjects: 41
Study 38822391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 38822389 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld fluorescence imaging device with 5-aminolevulinic acid (5-ALA) administration
Number of subjects: 0
Study 38822389 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld fluorescence imaging device
Number of subjects: 0
Study 38822758 — intervention group
Group type: EXPERIMENTAL
Intervention: Taletrectinib
Number of subjects: 173
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract symptoms (LUTS)
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary tract dysfunction (LUTD)
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding maneuvers
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary urgency
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime urinary incontinence
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Enuresis
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional Voiding and Incontinence Scoring System (DVISS)
Number of subjects: 45
Study 38822858 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS score
Number of subjects: 45
Study 38822943 — intervention group
Group type: COMPARATOR
Intervention: IV CM-101 2.5 mg/kg
Number of subjects: 100
Study 38822943 — intervention group
Group type: COMPARATOR
Intervention: SC CM-101 5.0 mg/kg
Number of subjects: 100
Study 38822943 — intervention group
Group type: COMPARATOR
Intervention: IV CM-101 (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10.0 mg/kg)
Number of subjects: 100
Study 38822943 — intervention group
Group type: EXPERIMENTAL
Intervention: IV CM-101
Number of subjects: 100
Study 38822943 — intervention group
Group type: EXPERIMENTAL
Intervention: SC CM-101
Number of subjects: 100
Study 38822948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL, 595 nm)
Number of subjects: 60
Study 38822948 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL with Delicate Pulse Light (DPL, 500-600 nm)
Number of subjects: 60
Study 38822948 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL with M22 590 (590-1200 nm)
Number of subjects: 60
Study 38822948 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL with M22 vascular filter (530-650 nm and 900-1200 nm)
Number of subjects: 60
Study 38822948 — intervention group
Group type: COMPARATOR
Intervention: All four laser treatments
Number of subjects: 60
Study 38822948 — intervention group
Group type: COMPARATOR
Intervention: M22 vascular group
Number of subjects: 60
Study 38823034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (40 mg p.o. daily on days 1-21 of a 21-day cycle) and Pembrolizumab (200 mg i.v. on day 1)
Number of subjects: 27
Study 38823034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib and Pembrolizumab
Number of subjects: 27
Study 38823398 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus gemcitabine-cisplatin
Number of subjects: 914
Study 38823398 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine-cisplatin
Number of subjects: 914
Study 38823410 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-B01D1 at 3·0 mg/kg on days 1 and 8 every 3 weeks
Number of subjects: 195
Study 38823410 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-B01D1 at 6·0 mg/kg on day 1 every 3 weeks
Number of subjects: 195
Study 38823410 — intervention group
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Number of subjects: 195
Study 38823511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 260
Study 38823511 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 260
Study 38823603 — intervention group
Group type: EXPERIMENTAL
Intervention: High fear of movement (FOM) as measured by the Tampa Scale of Kinesiophobia-11
Number of subjects: 135
Study 38823603 — intervention group
Group type: COMPARATOR
Intervention: Low fear of movement (FOM) as measured by the Tampa Scale of Kinesiophobia-11
Number of subjects: 135
Study 38823849 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC hummus meal
Number of subjects: 15
Study 38823849 — intervention group
Group type: COMPARATOR
Intervention: RCC hummus meal
Number of subjects: 15
Study 38824242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus paclitaxel
Number of subjects: 703
Study 38824242 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 703
Study 38824243 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 357
Study 38824243 — intervention group
Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 357
Study 38824244 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of KAT6A and KAT6B
Number of subjects: 0
Study 38824432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 3048
Study 38824432 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 3048
Study 38824442 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped palliative care (initial visit within 4 weeks, subsequent visits based on treatment changes or hospitalizations)
Number of subjects: 507
Study 38824442 — intervention group
Group type: COMPARATOR
Intervention: Early palliative care (visits every 4 weeks after enrollment)
Number of subjects: 507
Study 38824442 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped palliative care
Number of subjects: 507
Study 38824442 — intervention group
Group type: COMPARATOR
Intervention: Early palliative care
Number of subjects: 507
Study 38824537 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based team training intervention
Number of subjects: 0
Study 38824537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulation-based team training)
Number of subjects: 0
Study 38824540 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia Forte (EF)
Number of subjects: 152
Study 38824540 — intervention group
Group type: COMPARATOR
Intervention: Riva Self Cure (RSC)
Number of subjects: 152
Study 38824540 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 152
Study 38824583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide gargle
Number of subjects: 100
Study 38824583 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine gargle
Number of subjects: 100
Study 38824626 — intervention group
Group type: EXPERIMENTAL
Intervention: Centanafadine
Number of subjects: 0
Study 38824626 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine
Number of subjects: 0
Study 38824626 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 0
Study 38824626 — intervention group
Group type: COMPARATOR
Intervention: Viloxazine ER
Number of subjects: 0
Study 38824658 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 61
Study 38824658 — intervention group
Group type: EXPERIMENTAL
Intervention: molecularly matched therapy
Number of subjects: 61
Study 38824836 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-cement coated plate
Number of subjects: 0
Study 38824836 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 0
Study 38824872 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthro-distension with early and intensive mobilization (ADM)
Number of subjects: 66
Study 38824872 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular steroid injection (ISI)
Number of subjects: 66
Study 38824899 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of telerehabilitation training (EG)
Number of subjects: 182
Study 38824899 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 182
Study 38824918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 100
Study 38824918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea PK dosing
Number of subjects: 100
Study 38824918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea default dose
Number of subjects: 100
Study 38824941 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg intravenously once every 3 weeks for 12 cycles)
Number of subjects: 425
Study 38824941 — intervention group
Group type: COMPARATOR
Intervention: standard therapy (gemcitabine and cisplatin induction chemotherapy followed by concurrent cisplatin radiotherapy)
Number of subjects: 425
Study 38824941 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab
Number of subjects: 425